Amyris, Inc. (NASDAQ:AMRS – Get Score) Director Frank Kung offered 200,000 shares of the inventory in a transaction that occurred on Wednesday, September twenty first. The shares had been offered at a mean worth of $3.50, for a complete transaction of $700,000.00. Following the completion of the sale, the director now straight owns 80,000 shares of the corporate’s inventory, valued at roughly $280,000. The sale was disclosed in a doc filed with the Securities & Trade Fee, which could be accessed by way of this hyperlink.
Frank Kung additionally just lately made the next commerce(s):
- On Monday, September nineteenth, Frank Kung offered 1,080,676 shares of Amyris inventory. The shares had been offered at a mean worth of $3.80, for a complete transaction of $4,106,568.80.
- On Thursday, September fifteenth, Frank Kung offered 1,385,000 shares of Amyris inventory. The shares had been offered at a mean worth of $4.20, for a complete transaction of $5,817,000.00.
Amyris Inventory Down 4.7 %
Shares of AMRS inventory traded down $0.16 throughout mid-day buying and selling on Thursday, reaching $3.22. 4,678,658 shares of the corporate had been exchanged, in comparison with its common quantity of 6,480,745. Amyris, Inc. has a fifty-two week low of $1.47 and a fifty-two week excessive of $15.12. The corporate has a debt-to-equity ratio of 1.26, a fast ratio of 1.13 and a present ratio of 1.66. The corporate has a market capitalization of $1.04 billion, a P/E ratio of -2.13 and a beta of 1.36. The enterprise’s 50 day easy shifting common is $2.81 and its 200 day easy shifting common is $3.03.
Amyris (NASDAQ:AMRS – Get Score) final launched its quarterly earnings outcomes on Tuesday, August ninth. The biotechnology firm reported ($0.34) earnings per share for the quarter, lacking analysts’ consensus estimates of ($0.28) by ($0.06). The agency had income of $65.20 million for the quarter, in comparison with analyst estimates of $81.53 million. Throughout the identical interval within the prior 12 months, the agency earned ($0.16) earnings per share. The corporate’s quarterly income was up 24.7% on a year-over-year foundation. Analysis analysts predict that Amyris, Inc. will put up -1.11 earnings per share for the present 12 months.
Wall Avenue Analysts Forecast Development
AMRS has been the topic of a number of latest analysis stories. Roth Capital downgraded shares of Amyris from a “purchase” ranking to a “impartial” ranking in a analysis report on Wednesday, August tenth. JPMorgan Chase & Co. initiated protection on shares of Amyris in a analysis report on Friday, June twenty fourth. They issued a “impartial” ranking for the corporate. Lastly, Piper Sandler elevated their worth goal on shares of Amyris from $2.50 to $4.00 and gave the corporate a “impartial” ranking in a analysis report on Monday.
Institutional Buying and selling of Amyris
Hedge funds have just lately made adjustments to their positions within the inventory. Farallon Capital Administration LLC lifted its stake in Amyris by 55.9% throughout the first quarter. Farallon Capital Administration LLC now owns 16,931,427 shares of the biotechnology firm’s inventory price $73,821,000 after buying a further 6,071,616 shares over the past quarter. Edmond DE Rothschild Holding S.A. lifted its stake in Amyris by 52.6% throughout the second quarter. Edmond DE Rothschild Holding S.A. now owns 6,965,700 shares of the biotechnology firm’s inventory price $12,887,000 after buying a further 2,401,900 shares over the past quarter. State of Michigan Retirement System lifted its stake in Amyris by 92.2% throughout the first quarter. State of Michigan Retirement System now owns 4,815,000 shares of the biotechnology firm’s inventory price $20,993,000 after buying a further 2,310,000 shares over the past quarter. Financial institution of Montreal Can purchased a brand new place in Amyris throughout the fourth quarter price $8,443,000. Lastly, Laurion Capital Administration LP purchased a brand new place in Amyris throughout the fourth quarter price $6,704,000. Institutional buyers and hedge funds personal 43.08% of the corporate’s inventory.
About Amyris
(Get Score)
Amyris, Inc, an artificial biotechnology firm, operates within the clear well being and wonder, and flavors and perfume markets in Europe, North America, Asia, and South America. The corporate manufactures and sells clear magnificence, private care, and well being and wellness shopper merchandise, in addition to substances to the flavour and perfume, diet, meals and beverage, and clear magnificence and private care finish markets.
Really useful Tales
This on the spot information alert was generated by narrative science expertise and monetary information from MarketBeat with a view to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial workforce previous to publication. Please ship any questions or feedback about this story to contact@marketbeat.com.
Earlier than you take into account Amyris, you may wish to hear this.
MarketBeat retains observe of Wall Avenue’s top-rated and greatest performing analysis analysts and the shares they suggest to their shoppers every day. MarketBeat has recognized the 5 shares that prime analysts are quietly whispering to their shoppers to purchase now earlier than the broader market catches on… and Amyris wasn’t on the record.
Whereas Amyris presently has a “Maintain” ranking amongst analysts, top-rated analysts consider these 5 shares are higher buys.
View The 5 Shares Right here
